We’re charting a new path to advance psychedelic medicine.

There are nearly 1 billion people in the world suffering from a mental health disorder.

Psychedelic therapy has been proven to be a breakthrough mental health treatment. Ketamine, MDMA, and psilocybin are making advancements through the FDA, but the process is inefficient.

We need to make psychedelic therapy accessible, so more people can begin healing now.

That's why we built Maya. We use real world evidence to inform clinical practices, drug development, and regulation to support safe, effective, and accessible psychedelic practices.

Our platform supports three major stakeholders:


We give researchers access to unique real world data that can inform clinical trial design and commercialization strategies, and optimize trial outcomes.

Learn more


We save providers time by automating screening, intake, preparation, and integration. Practice analytics inform greater health outcomes.

Learn more


We offer those receiving psychedelic therapy the opportunity to feel safe, gain insight into their healing journey, and learn about their own process.

Coming soon

World-renowned leaders have partnered with us.

Over the past few years, we’ve earned partnerships with some of the most innovative companies and organizations in the field.

Imperial College London logo
UCSF logo
Speak logo
Microdose Psychedelic Insights logo
Halugen logo
Myco meditations logo
The third wave logo
Wavepaths logo
Vote nature logo
PSFC  logo
Psychedelic Medicine Association logo
Lucid News logo
Sigmind logo
Naropa logo
Neuroscape logo
Heroic Hearts project logo
Mydecine logo

We are deeply rooted in the psychedelic and research community.

Our work stems from our background in academic research with Johns Hopkins University through Unlimited Sciences. Following our involvement helping Denver become the first city to decriminalize psilocybin mushrooms, we have become deeply connected with psychedelic practitioners and researchers all over the world.

About Us

There is much important work to be done in understanding how psychedelic medicines can be utilized safely while maximizing the benefit. I believe the work Maya and its team are doing is exceptional in this regard. It is exactly what is needed to help positively shape the industry while supporting us all to reach a greater stage in human development.

Dr. Dan Engle

Psychiatrist, Founder, Kuya Treatment Center

One of Maya’s major contributions is to make it more of the norm for practitioners to collect data, so they are able to demonstrate the value of psychedelic therapy.

Robin Carhart-Harris

Director of Psychedelics Division, Neuroscape, UCSF

Next arrow line grey icon
Prev arrow line grey icon

Read our last article

Read More

Listen our last podcast

Read More